Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Feb;22(2):222-31.
doi: 10.1007/s00467-006-0286-0. Epub 2006 Nov 28.

Clinical outcomes of childhood lupus nephritis: a single center's experience

Affiliations

Clinical outcomes of childhood lupus nephritis: a single center's experience

Byong Sop Lee et al. Pediatr Nephrol. 2007 Feb.

Abstract

This study retrospectively reviewed the medical records of children with lupus nephritis (LN) who were treated at Seoul National University Children's Hospital from 1986 to 2005 (mean duration 8.3+/-4.4 years). The records of 77 children (22 male and 55 female) were examined. The mean age at diagnosis was 11.9+/-3.0 years. The initial biopsy results revealed a WHO class IV classification for 60 (88.2%) of 68 biopsy proven cases. Of 77 patients, 67 (87.0%) responded initially to the high-dose corticosteroids with or without additional immunosuppressive therapy. Of the initial responders (67), 30 (44.8%) experienced at least one episode of proteinuric (24) or nephritic (6) flare. Thirteen patients (16.9%) progressed to either chronic renal failure (CRF) or end-stage renal disease (ESRD). Six (7.8%) patients died. A Kaplan-Meier estimate of patient survival and CRF-free survival rate was 95.4% and 88.7% at 5 years and 91.8% and 74.7% at 10 years, respectively. Multivariate analysis for class IV LN revealed male gender (P=0.029), initial hypertension (P=0.001) and absence of remission (P=0.002) to be prognostic factors predicting CRF. Glomerulosclerosis of 10% or more (P=0.005), nephritic flare (P=0.011), and presence of anti-phospholipid antibody (P=0.017) or syndrome (P=0.004) were also found to be independent risk factors for CRF. Cyclophosphamide pulse therapy failed to demonstrate superiority over other combined immunosuppressants used for the treatment of diffuse proliferative LN.

PubMed Disclaimer

References

    1. J Am Soc Nephrol. 2005 Apr;16(4):1076-84 - PubMed
    1. Arthritis Rheum. 2004 Dec;50(12):3934-40 - PubMed
    1. J Rheumatol. 1993 Oct;20(10):1684-93 - PubMed
    1. Curr Opin Rheumatol. 1999 Sep;11(5):352-6 - PubMed
    1. J Am Soc Nephrol. 1996 Jun;7(6):924-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources